Atlas FDA

ABBOTT AXSYM ANTIBODY TO HCV

FDA premarket approval P970027 · decided 2004-02-05

Approval details

PMA number
P970027
Trade name
ABBOTT AXSYM ANTIBODY TO HCV
Generic name
Assay, enzyme linked immunosorbent, hepatitis c virus
Applicant
Abbott Laboratories
Date received
1997-07-01
Decision date
2004-02-05
Days to decision
2410 days
Decision code
APWD
Product code
MZO
Advisory committee
Microbiology
Expedited review
No
Location
Abbott Park, IL
Statement
APPROVAL FOR THE ABBOTT AXSYM ANTIBODY TO HCV. THE DEVICE IS INDICATED FOR THE QUALITATIVE DETECTION OF ANTI-HCV RECOMBINANT PROTEINS IN HUMAN SERUM OR PLASMA (POTASSIUM EDTA, SODIUM EDTA, SODIUM HEPARIN, LITHIUM HEPARIN, SODIUM CITRATE, AND POTASSIUM OXALATE).

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Anti-HCV Next (K252424)Abbott Laboratories2026-04-28
ARCHITECT iGentamicin (K243500)Abbott Laboratories2025-07-09
Alinity i Rubella IgG (K243168)Abbott Laboratories2025-06-20
Alinity h-series System (K243283)Abbott Laboratories2025-02-20
Alinity i Toxo IgM (K233932)Abbott Laboratories2024-08-30
TBI (K232669)Abbott Laboratories2023-09-29
HAVAb IgG II (K222850)Abbott Laboratories2023-08-10
Alinity h-series System (K220031)Abbott Laboratories2023-08-04